Gut microbiome in non-alcoholic fatty liver disease
Open Access
- 14 January 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Gastroenterology
- Vol. 3, 1534431
Abstract
Non-alcoholic fatty liver disease (NAFLD) has a rapidly growing incidence worldwide, affecting approximately one-third of world population. The disturbance of gut commensal bacteria impacting host’s homeostasis is referred to as gut dysbiosis. The gut microbiome contributes to the pathogenesis of NAFLD through various pathways. Gut microbiota is at constant interactions with the intestinal epithelial barrier and affects its integrity. Through gut-liver axis, gut microbiota may influence liver immune function. The release of lipopolysaccharides (LPS) from intestines to portal vein which are transported to the liver, may trigger hepatic inflammation, steatosis and even fibrosis. Moreover, the gut microbiome induces the conversion of primary bile acids (BAs) to secondary BAs, which activates intestinal receptors, such as FXR and TGR5. FXR activation decreases fat absorption and thus reduces hepatic lipid accumulation, while TGR5 activation promotes the release of glucagon-like peptide-1 (GLP-1) in blood. Furthermore, gut ethanol-producing bacteria has been implicated in NAFLD development. Additionally, in NAFLD there is a reduction in intestinal levels of short-chain fatty acids, such as butyrate, propionate and acetate. Many bacterial alterations have been observed in NAFLD, including the increased Bacteroidetes and decreased Firmicutes. Many probiotics have been tried in NAFLD prevention and management, including a plethora of strains from Lactobacilli, Bifidobacteria and Streptococcus and some of them have promising perspectives. There is also some promising data from the administration of prebiotics (such as inulin and fructo-oligosaccharides) and symbiotics (probiotics plus prebiotics). Faecal microbiota transplantation (FMT) is yet to be evaluated for its efficacy against NAFLD.Keywords
This publication has 167 references indexed in Scilit:
- Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile)Cochrane Database of Systematic Reviews, 2023
- NAFLD‐related hepatocellular carcinoma: The growing challengeHepatology, 2022
- Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With SteatohepatitisHepatology Communications, 2020
- Bile acids and nonalcoholic fatty liver diseaseHepatology, 2017
- Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta‐omics‐based approachHepatology, 2016
- The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiotaHepatology, 2015
- Intestinal microbiota in patients with nonalcoholic fatty liver diseaseHepatology, 2013
- Characterization of Gut Microbiomes in Nonalcoholic Steatohepatitis (NASH) Patients: A Connection Between Endogenous Alcohol and NASHHepatology, 2012
- The G-Protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) in miceHepatology, 2011
- Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease†Hepatology, 2009